Charles M. Gerrits

1.4k total citations
19 papers, 1.0k citations indexed

About

Charles M. Gerrits is a scholar working on Cardiology and Cardiovascular Medicine, Toxicology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Charles M. Gerrits has authored 19 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Cardiology and Cardiovascular Medicine, 6 papers in Toxicology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Charles M. Gerrits's work include Pharmacovigilance and Adverse Drug Reactions (6 papers), Diabetes Treatment and Management (4 papers) and Computational Drug Discovery Methods (2 papers). Charles M. Gerrits is often cited by papers focused on Pharmacovigilance and Adverse Drug Reactions (6 papers), Diabetes Treatment and Management (4 papers) and Computational Drug Discovery Methods (2 papers). Charles M. Gerrits collaborates with scholars based in United States, Netherlands and United Kingdom. Charles M. Gerrits's co-authors include Manfred Hauben, Louisa Walsh, David Madigan, Eugène van Puijenbroek, Eric Q. Wu, James Signorovitch, Evan Kantor, Yanjun Bao, Andrew P. Yu and Parvez Mulani and has published in prestigious journals such as Neurology, Diabetes and European Respiratory Journal.

In The Last Decade

Charles M. Gerrits

19 papers receiving 967 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Charles M. Gerrits United States 14 337 168 164 144 135 19 1.0k
Susan T. Sacks United States 16 501 1.5× 130 0.8× 136 0.8× 64 0.4× 139 1.0× 39 1.8k
Kaori Kadoyama Japan 14 499 1.5× 72 0.4× 152 0.9× 57 0.4× 126 0.9× 25 1.3k
Akiko Tamon Japan 8 344 1.0× 37 0.2× 73 0.4× 100 0.7× 231 1.7× 12 969
Frantz Thiessard France 20 469 1.4× 130 0.8× 40 0.2× 38 0.3× 151 1.1× 60 1.2k
Tomomi Kimura Japan 21 111 0.3× 54 0.3× 371 2.3× 94 0.7× 236 1.7× 91 1.5k
Lynette Swartz United States 6 248 0.7× 56 0.3× 44 0.3× 95 0.7× 63 0.5× 6 990
C. Kreft-Jaïs France 14 249 0.7× 40 0.2× 58 0.4× 211 1.5× 67 0.5× 38 774
Stella G. Machado United States 10 340 1.0× 149 0.9× 40 0.2× 26 0.2× 128 0.9× 17 969
Sarah Watson Sweden 9 208 0.6× 23 0.1× 57 0.3× 119 0.8× 129 1.0× 18 868
Ola Caster Sweden 14 451 1.3× 103 0.6× 32 0.2× 19 0.1× 62 0.5× 26 832

Countries citing papers authored by Charles M. Gerrits

Since Specialization
Citations

This map shows the geographic impact of Charles M. Gerrits's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charles M. Gerrits with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charles M. Gerrits more than expected).

Fields of papers citing papers by Charles M. Gerrits

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charles M. Gerrits. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charles M. Gerrits. The network helps show where Charles M. Gerrits may publish in the future.

Co-authorship network of co-authors of Charles M. Gerrits

This figure shows the co-authorship network connecting the top 25 collaborators of Charles M. Gerrits. A scholar is included among the top collaborators of Charles M. Gerrits based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charles M. Gerrits. Charles M. Gerrits is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
2.
Gerrits, Charles M., Gautam Sajeev, James Signorovitch, et al.. (2019). Eteplirsen Delays Time to Loss of Ambulation in Patients With Duchenne Muscular Dystrophy Compared With Patients Receiving Standard of Care. Neuropediatrics. 1 indexed citations
3.
Tuttle, Edward, et al.. (2018). Patient Quality of Life and Benefits of Leptin Replacement Therapy (LRT) in Generalized and Partial Lipodystrophy (GL, PL). Diabetes. 67(Supplement_1). 2 indexed citations
4.
Chou, Engels, et al.. (2017). Economic burden of hypoglycemia with basal insulin in type 2 diabetes.. PubMed. 23(2). 114–122. 14 indexed citations
5.
Freemantle, Nick, Engels Chou, Ying Daisy Zhuo, et al.. (2016). Safety and efficacy of insulin glargine 300 u/mL compared with other basal insulin therapies in patients with type 2 diabetes mellitus: a network meta-analysis. BMJ Open. 6(2). e009421–e009421. 49 indexed citations
6.
Signorovitch, James, Eric Q. Wu, Andrew P. Yu, et al.. (2010). Comparative Effectiveness Without Head-to-Head Trials. PharmacoEconomics. 28(10). 935–945. 258 indexed citations
7.
Hauben, Manfred, Lester Reich, Charles M. Gerrits, & Muhammad Younus. (2007). Illusions of objectivity and a recommendation for reporting data mining results. European Journal of Clinical Pharmacology. 63(5). 517–521. 18 indexed citations
8.
Gerrits, Charles M., Mondira Bhattacharya, Shivaji Manthena, et al.. (2007). A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes. Pharmacoepidemiology and Drug Safety. 16(10). 1065–1071. 67 indexed citations
9.
Hauben, Manfred, Lester Reich, Charles M. Gerrits, & David Madigan. (2007). Detection of Spironolactone-Associated Hyperkalaemia Following the Randomized Aldactone Evaluation Study (RALES). Drug Safety. 30(12). 1143–1149. 16 indexed citations
10.
Gerrits, Charles M., Mondira Bhattacharya, Shivaji Manthena, et al.. (2007). A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes. Pharmacoepidemiology and Drug Safety. 16(12). 1314–1316. 7 indexed citations
11.
Hauben, Manfred, Lester Reich, & Charles M. Gerrits. (2006). Reports of hyperkalemia after publication of RALES—a pharmacovigilance study. Pharmacoepidemiology and Drug Safety. 15(11). 775–783. 15 indexed citations
12.
Hauben, Manfred, David Madigan, Charles M. Gerrits, Louisa Walsh, & Eugène van Puijenbroek. (2005). The role of data mining in pharmacovigilance. Expert Opinion on Drug Safety. 4(5). 929–948. 190 indexed citations
13.
Almenoff, June S., Joseph M. Tonning, A. Lawrence Gould, et al.. (2005). Perspectives on the Use of Data Mining in Pharmacovigilance. Drug Safety. 28(11). 981–1007. 173 indexed citations
14.
Hauben, Manfred, Vaishali Patadia, Charles M. Gerrits, Louisa Walsh, & Lester Reich. (2005). Data Mining in Pharmacovigilance. Drug Safety. 28(10). 835–842. 42 indexed citations
15.
Breekveldt‐Postma, Nancy S., Charles M. Gerrits, J.-W.J. Lammers, J. A. M. Raaijmakers, & Ron M. C. Herings. (2004). Persistence with inhaled corticosteroid therapy in daily practice. Respiratory Medicine. 98(8). 752–759. 44 indexed citations
16.
Gerrits, Charles M., et al.. (2003). N-acetylcysteine reduces the risk of re-hospitalisation among patients with chronic obstructive pulmonary disease. European Respiratory Journal. 21(5). 795–798. 73 indexed citations
17.
Gerrits, Charles M., et al.. (1999). Asthma exacerbations during first therapy with long acting beta 2-agonists.. Pharmacy World & Science. 21(3). 116–119. 6 indexed citations
18.
Moll, Frans L., et al.. (1996). The relationship between sigmoidal intramucosal pH and intestinal arterial occlusion during aortic reconstructive surgery. European Journal of Vascular and Endovascular Surgery. 11(3). 304–307. 13 indexed citations
19.
Mulder, Chris J., et al.. (1989). Omeprazole (20 mg o.m.) versus ranitidine (150 mg b.d.) in duodenal ulcer healing and pain relief. Alimentary Pharmacology & Therapeutics. 3(5). 445–451. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Susan T. Sacks Breakdown of academic impact, for papers by Kaori Kadoyama Breakdown of academic impact, for papers by Akiko Tamon Breakdown of academic impact, for papers by Frantz Thiessard Breakdown of academic impact, for papers by Tomomi Kimura Breakdown of academic impact, for papers by Lynette Swartz Breakdown of academic impact, for papers by C. Kreft-Jaïs Breakdown of academic impact, for papers by Stella G. Machado Breakdown of academic impact, for papers by Sarah Watson Breakdown of academic impact, for papers by Ola Caster
Rankless by CCL
2026